JP2011225577A5 - - Google Patents

Download PDF

Info

Publication number
JP2011225577A5
JP2011225577A5 JP2011121017A JP2011121017A JP2011225577A5 JP 2011225577 A5 JP2011225577 A5 JP 2011225577A5 JP 2011121017 A JP2011121017 A JP 2011121017A JP 2011121017 A JP2011121017 A JP 2011121017A JP 2011225577 A5 JP2011225577 A5 JP 2011225577A5
Authority
JP
Japan
Prior art keywords
agent
remyelinating
treat
preparing
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011121017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011225577A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011225577A publication Critical patent/JP2011225577A/ja
Publication of JP2011225577A5 publication Critical patent/JP2011225577A5/ja
Pending legal-status Critical Current

Links

JP2011121017A 2003-01-24 2011-05-30 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療 Pending JP2011225577A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44217103P 2003-01-24 2003-01-24
US60/442,171 2003-01-24
US50031603P 2003-09-05 2003-09-05
US60/500,316 2003-09-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006503001A Division JP2007521249A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013210543A Division JP2014040458A (ja) 2003-01-24 2013-10-07 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Publications (2)

Publication Number Publication Date
JP2011225577A JP2011225577A (ja) 2011-11-10
JP2011225577A5 true JP2011225577A5 (enExample) 2012-08-30

Family

ID=32829779

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006502997A Pending JP2006516624A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2006503001A Pending JP2007521249A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2011121017A Pending JP2011225577A (ja) 2003-01-24 2011-05-30 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2013210543A Pending JP2014040458A (ja) 2003-01-24 2013-10-07 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006502997A Pending JP2006516624A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2006503001A Pending JP2007521249A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013210543A Pending JP2014040458A (ja) 2003-01-24 2013-10-07 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Country Status (16)

Country Link
US (2) US20050069541A1 (enExample)
EP (4) EP3527228A1 (enExample)
JP (4) JP2006516624A (enExample)
KR (2) KR20050114212A (enExample)
AU (5) AU2004207535A1 (enExample)
CA (2) CA2514125A1 (enExample)
CO (1) CO5670359A2 (enExample)
IL (1) IL169770A (enExample)
MX (2) MXPA05007843A (enExample)
NO (1) NO20053920L (enExample)
PE (1) PE20040942A1 (enExample)
RU (1) RU2412721C2 (enExample)
SK (1) SK50642005A3 (enExample)
TW (2) TW201311238A (enExample)
UY (1) UY28170A1 (enExample)
WO (2) WO2004066932A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
KR20050114212A (ko) 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
EP1706399A1 (en) 2004-01-23 2006-10-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AR050425A1 (es) * 2004-07-08 2006-10-25 Elan Pharm Inc Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
EP1888639A1 (en) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
US8030328B2 (en) 2005-05-20 2011-10-04 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives
US20070106035A1 (en) * 2005-10-26 2007-05-10 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
CA2667944A1 (en) * 2005-10-26 2007-05-03 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US9008378B2 (en) 2006-12-20 2015-04-14 The Board Of Trustees Of The Leland Stanford Junior University Arrangement and imaging of biological samples
EP2198040B1 (en) * 2007-08-31 2018-08-15 Case Western Reserve University In vivo imaging of myelin
AU2009298888A1 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
SG175166A1 (en) * 2009-04-17 2011-11-28 Biogen Idec Inc Compositions and methods to treat acute myelogenous leukemia
WO2011020874A1 (en) * 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
PT2558499T (pt) 2010-04-16 2017-07-14 Biogen Ma Inc Anticorpos anti-vla-4
WO2012012147A2 (en) * 2010-06-30 2012-01-26 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
JP5847188B2 (ja) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
AR084141A1 (es) * 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
US9428472B2 (en) 2011-08-16 2016-08-30 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
PT3590960T (pt) 2012-02-29 2023-04-18 Takeda Pharmaceuticals Co Remielinização estimulada por igg de nervos periféricos
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
HK1213794A1 (zh) * 2012-10-09 2016-07-15 Biogen Ma Inc. 联合治疗及用於治疗脱髓鞘病症的用途
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
ES2744526T3 (es) 2014-03-12 2020-02-25 Prothena Biosciences Ltd Anticuerpos anti-MCAM y métodos de uso asociados
KR20170052526A (ko) * 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
KR102364840B1 (ko) 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
EP3229797A4 (en) * 2014-12-12 2018-08-15 Commonwealth Scientific and Industrial Research Organisation Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists
US10738121B2 (en) 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN106316982B (zh) 2015-06-30 2020-08-14 中国人民解放军军事医学科学院毒物药物研究所 噻嗪酰胺衍生物及其用途
US10947311B2 (en) * 2015-11-20 2021-03-16 The Board Of Trustees Of The Leland Stanford Junior University VCAM-1 mediated methods and compositions for treating aging-associated impairments
AU2019274649B2 (en) * 2018-05-23 2025-10-09 Csl Behring Ag Treatment of CIDP
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
SU1718797A1 (ru) * 1990-01-04 1992-03-15 Ленинградский Государственный Институт Усовершенствования Врачей Им.С.М.Кирова Способ дифференциальной диагностики поражени нервных стволов
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6306384B1 (en) 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP2001517245A (ja) * 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
DE69834642T2 (de) * 1997-07-31 2007-05-03 Elan Pharmaceuticals, Inc., South San Francisco Verbindungen mit einer 4-amino-phenylalaningruppe, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
IL133640A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
US6362341B1 (en) * 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) * 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) * 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
AU8823498A (en) * 1997-07-31 1999-02-22 American Home Products Corporation Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
CA2291473A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1185250C (zh) * 1999-01-25 2005-01-19 依兰制药公司 可以抑制由vla－4介导的白细胞粘着的化合物
EP1148889A2 (en) * 1999-01-29 2001-10-31 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
EP1253923A1 (en) 2000-01-28 2002-11-06 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
EP1294770B1 (en) * 2000-05-10 2011-12-07 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6653313B2 (en) * 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
AU2001292846A1 (en) * 2000-09-20 2002-04-29 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
KR20050114212A (ko) 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor

Similar Documents

Publication Publication Date Title
JP2011225577A5 (enExample)
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
HK1206055A1 (en) Methods and processes for non-invasive assessment of genetic variations
MX2014002087A (es) Formulaciones piretroides.
JP2012143233A5 (enExample)
GB201220065D0 (en) Matrix for generating and cultivating uniform cell aggregations, method for producing a matrix and use of a matrix
ZA201401562B (en) Agrochemical composition uses and preparation process thereof, as well as method to ensure high crop yield
EP2851119A4 (en) CATALYST FOR USE IN THE PREPARATION OF METACRYLIC ACID, METHOD FOR THE PRODUCTION OF THE CATALYST AND METHACRYLIC ACID PROCESS FOR THE PREPARATION OF THIS CATALYST
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
IL228951A0 (en) Methods and preparations for modulating gene expression by using components that are assembled independently in cells and produce rnai activity
DK201300530A (en) Vaccine relating to Pancreas disease in fish
PT2859092T (pt) ¿vacina terapêutica para tratamento de diabetes tipo 1 em crianças, aplicação do separador de células e método de multiplicação de células treg para produzir a vacina terapêutica para tratamento de diabetes tipo 1¿
IL232642A0 (en) A method for characterizing circulating cells and its use in diagnosis
EP2825040A4 (en) PROCESS FOR PREPARING BENZAZOQUOOLIUM (BQS) SALTS, USE OF THE COMPOSITION AS CELLULAR MARKERS AND USE OF THE BIOLOGICAL ACTIVITY OF THIS COMPOSITION
LU91877B1 (en) Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy
EP2730585A4 (en) PROTEIN-PEPTIDE COMPLEX HAVING SPECIFIC ACTION ON DERMAL TISSUES, PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
SG11201502292WA (en) Method for producing extended-release potassium citrate wax matrix tablet
PL393021A1 (pl) Nowy szczep Trichoderma o podwyższonej aktywności biologicznej, zwłaszcza do stosowania w rolnictwie jako biofungicyd oraz sposób wytwarzania tego szczepu
EP2697239A4 (en) N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
EP2730586A4 (en) PROTEIN-PEPTIDE COMPLEX HAVING SPECIFIC ACTION ON DERMAL TISSUES, PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
BRPI1006471A2 (pt) composição aquosa, para processo para a preparação de uma composição, uso de sal para desacelarar o crescimento da particula em uma composição aquosa, uso da composição e semente
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
PL395684A1 (pl) Nawóz cynkowy w formie zawiesiny zawierajacej tlenek cynku, sposób wytwarzania nawozu cynkowego w formie zawiesiny zawierajacej tlenek cynku oraz zastosowanie nawozu cynkowego w formie zawiesiny zawierajacej tlenek cynku
EP2692351A4 (en) ACTIVE FRACTION OF PAULLINIA CUPANA WITH IMPROVED EFFICACY AGAINST TEMPTATION, PROCESS FOR PREPARING AN ACTIVE FRACTION, USE THEREOF, PHARMACEUTICAL COMPOSITION, MEDICAMENTS AND TREATMENT FOR TREATMENT